10 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Identification of new SUMO activating enzyme 1 inhibitors using virtual screening and scaffold hopping.
Riken
Identification of quinazolinyloxy biaryl urea as a new class of SUMO activating enzyme 1 inhibitors.
Riken
Exploring a new frontier in cancer treatment: targeting the ubiquitin and ubiquitin-like activating enzymes.
University of Toronto Mississauga
NAE modulators: A potential therapy for gastric carcinoma.
Southwest Jiaotong University
Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer.
Millennium Pharmaceuticals, A Wholly Owned Subsidiary of Takeda Pharmaceuticals
Interrogating the Roles of Post-Translational Modifications of Non-Histone Proteins.
Temple University
Heteroaryl compounds useful as inhibitors of SUMO activating enzyme
Millennium Pharmaceuticals